Diabetic Nephropathy Type 2 Clinical Trial
Official title:
Antiproteinuric Efficacy of ACE Inhibitors, Selective MRAs and ACE Inhibitor/Selective MRA Combination Therapy in Diabetic Hypertensives With Microalbuminuria
The aim of our work is to compare the antiproteinuric efficacy of ACEI monotherapy, Selective MRA monotherapy and their combination in mildly hypertensive patients with type 2 diabetes mellitus and microalbuminuria
Diabetic nephropathy (DN) is the most common cause renal failure in Western countries, responsible for 45% of patients on renal replacement therapy.Diabetic nephropathy was characterized in the early stage by increased albumin excretion in urine, known as microalbuminuria. (DN) results from interactions between different pathological factors that include hyperglycemia, increased activity of the renin-angiotensin-aldosterone-system (RAAS), uncontrolled high systemic and glomerular pressure . (DN) optimal therapy continues to evolve. The main lines of treatment include strict glycemic and blood pressure (BP) control. The angiotensin converting enzyme (ACE) inhibitors have been known to reduce proteinuria both in normotensive and hypertensive patients with diabetic nephropathy and in hypertensive individuals with end stage renal failure . The mechanism by which ACE inhibitors exert their effect on proteinuria reduction is still unknown. The control of high systemic arterial pressure can be beneficial by reducing the filtration pressure. However, no association has been found between antihypertensive effect and proteinuria reduction in several studies. Microalbuminuria which is an early sign of nephropathy can be decreased also by use of Angiotensin receptor blockers (ARBs) in patients with type 2 diabetes mellitus . Insufficient blockade of aldosterone may lead to inadequate anti-albuminuric effects. Studies show that renin-angiotensin-aldosterone system inhibition with ACEI/ARB alone sometimes does not achieve optimal renoprotective effects and does not reduce progression of renal disease, despite therapy. Addition of mineralocorticoid receptor antagonists (MRAs) to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy was found to reduce proteinuria in patients diabetic nephropathy and can delay progression of renal dysfunction. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
| Completed |
NCT04549324 -
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
|
||
| Recruiting |
NCT03502031 -
Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy
|
Phase 4 | |
| Completed |
NCT03681704 -
the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD
|
Phase 1 | |
| Completed |
NCT03681249 -
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
|
Early Phase 1 | |
| Withdrawn |
NCT03504566 -
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
|
Phase 4 | |
| Completed |
NCT03889236 -
Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.
|
N/A | |
| Completed |
NCT06326034 -
Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients
|
Phase 4 | |
| Recruiting |
NCT04931537 -
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
|
||
| Not yet recruiting |
NCT05373004 -
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03622762 -
Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy
|
Phase 2 | |
| Recruiting |
NCT03445247 -
Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy
|
N/A | |
| Not yet recruiting |
NCT06068439 -
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05487755 -
Investigational and Comparative Study in the Management of Diabetic Nephropathy
|
Phase 3 | |
| Not yet recruiting |
NCT06222476 -
Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.
|
N/A | |
| Active, not recruiting |
NCT04573920 -
Atrasentan in Patients With Proteinuric Glomerular Diseases
|
Phase 2 | |
| Recruiting |
NCT05888909 -
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
|
||
| Not yet recruiting |
NCT04962399 -
Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
|
||
| Not yet recruiting |
NCT03591939 -
T-regulatory Cells in Diabetic Type Two Nephropathy
|
||
| Active, not recruiting |
NCT03859817 -
Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient
|